#ACR23 Abstr# 2487 How to reduce PBO response in #SLE trials? Try adding low dose GC as co-primary endpoint. Interim analysis of Phase 2 RCT: SRI-4 + sustained GC dose to ≤5mg/d or ≤BL from Wk16 to 28 was met more in Ianalumab (BAFF-R-i) vs PBO (44% vs 9%) @RheumNow https://t.co/JEnMWKilR6

TM85 #ACR23 @RheumNow IPF s/p lung transplant p/w diffuse bone pain Exam: no synovitis, +crackles. Labs: ALP 203 CT chest: stable mycetoma Xray: periosteal reaction Dx: vericonazole periosititis Positive Mucorales PCR, fluoride level 19 (ref <4) Bone pain improved stopping voric https://t.co/Gt8mOAssvh

Anti-fibrotics in RA-ILD Retro analysis of 74 pts AEs frequent 55% and discontinuation in 46% (more than in initial RCTs) No diff between AF FCV trajectory mildly improved ABST2479 @RheumNow @Juge_P_A @PhilippeDieude #ACR23 https://t.co/GqsHxkIFgD

Rashes in Rheumatology at #ACR23 Which disease entity are these palms pathognomonic for? @RheumNow https://t.co/NmT1LTzWmm

Therapeutic Ladder for Discoid Lupus: 1. Strict🌞protection, smoking avoidance 2. Antimalarials 3. Topicals/intralesional corticosteroids, topical CNI 4. Oral steroids, retinoids, MTX, MMF 5. Thalidomide, lenalidomide 6. IVIG, JAKi, Belimumab... BUT also Anifrolumab!… https://t.co/xSw0s12Uvk https://t.co/stIJ944d9A

#ACR23 Abstr# 2485 Belimumab therapy in RCT was associated with increased risk of psychiatric events inc suicidality vs PBO. When compared with standard immunosuppressant, real-world data using emulated trial design showed no increased risk @RheumNow https://t.co/Vqhc5yRsSA

A new innovative way of teaching MS ultrasound to students using teledidactic teaching with portable ultrasound devices resulted in a significant increase in knowledge comparable to the conventional course, Schäfer SV, Abst#2079 #ACR23 @RheumNow https://t.co/re0gErx5ke https://t.co/yPbS9Rj0az

Late breaking at #ACR23: extension of this study for dazodalibep (anti-CD40L) for Sjogren’s symptoms Another six months with a crossover - & sustained symptomatic benefit after cessation. Fascinating, addresses a desperate clinical need, bring on the phase 3! ABSTL10 @RheumNow https://t.co/zUfnGEZefj https://t.co/S3lLwhwl85

Complements & HCQ? (Prof Petri et al) Significant ⬆️ in C3 (p=0.022) & C4 (p=0.003) levels with HCQ whole blood levels >50 ng/mL Increasing blood levels of HCQ significantly assocd w/⬆️prob of achieving normal C4 Improving C3,C4; addtl benefit of HCQ? #ACR23 ABST2327 @RheumNow https://t.co/5ucpXq9ngb

#ACR23 Abstr#2335 A step towards equal access to therapy for ANA+ people with arthritis. A cohort study showed: ANA+ (#SLE, #sjogren, MCTD, UCTD) & arthritis were homogenous related to clinical features, PROs & gene expression score. Offer rationale for basket trial @RheumNow https://t.co/7HTMxE7mSP

HCQ discontinuation in SLE? Why?! In this retro cohort of 42 pts Reasons: Retinal toxicity (57%) Self-discontinuation (17%) Factors strongly assoc'd w/ flares 1 yr after discontinuation - mean C3 and +dsDNA at index visit. #ACR23 ABST2343 @RheumNow https://t.co/BCO9N4gSkX